Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study
暂无分享,去创建一个
J. Stypmann | J. Garbade | H. Lehmkuhl | M. Barten | C. Bara | C. Knosalla | A. Doesch | S. Hirt | U. Schulz | C. Sieder | M. Porstner | C. Grinninger | Carola Grinninger
[1] J. Garbade,et al. The clinical impact of donor-specific antibodies in heart transplantation. , 2018, Transplantation reviews.
[2] M. Barten,et al. Renal protection strategies after heart transplantation , 2018, Clinical transplantation.
[3] J. D. de Fijter,et al. Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study , 2017, Transplantation.
[4] L. Lund,et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] F. Lehner,et al. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] A. Israni,et al. OPTN/SRTR 2015 Annual Data Report: Heart , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] J. Stypmann,et al. The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation. , 2015, Contemporary clinical trials.
[8] H. Bøtker,et al. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One‐Year Results of a Scandinavian Randomized Trial , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] G. Dellgren,et al. Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal in Heart Transplant Recipients: A Randomized Trial , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] G. Ewald,et al. Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] M. Cooper,et al. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. , 2012, Transplantation.
[12] R. Rodeheffer,et al. Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation , 2012, Circulation.
[13] D. Brennan,et al. Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] A. Jardine,et al. Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study , 2011, Transplantation.
[15] H. Fagertun,et al. Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial , 2010, Transplantation.
[16] G. Gerosa,et al. Everolimus With Reduced Cyclosporine Versus MMF With Standard Cyclosporine in De Novo Heart Transplant Recipients , 2009, Transplantation.
[17] N. Giannetti,et al. The Clinical Impact of an Early Decline in Kidney Function in Patients Following Heart Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] F. Schena,et al. Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.
[19] W. Kremers,et al. Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft , 2008, Transplantation.
[20] W. Kremers,et al. Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. , 2008, European heart journal.
[21] M. Weis,et al. Cardiac allograft vasculopathy: recent developments. , 2008, Circulation.
[22] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[23] F. Dumont,et al. Mechanism of action of the immunosuppressant rapamycin. , 1995, Life sciences.
[24] M. Hammond,et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.
[25] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[26] Silviu Itescu,et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.